All In Biotech

Drug Trial Radar · NCT06584032

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

A Randomized,Open-label,Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab Versus Chemotherapy of the Treating Physician's Choice as Second-line Treatment for Advanced Endometrial Cancer

Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 412 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

412

Planned (sponsor's estimate)

Start

Dec 12, 2024

Primary completion

Jan 8, 2029

Study completion Jun 9, 2029

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Sep 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).

Conditions

  • Advanced Endometrial Cancer

Interventions

  • fruquintinibDrug

    Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.

  • sintilimabBiological

    Sintilimab will be intravenously administrated on Day 1 every three weeks.

  • paclitaxelDrug

    175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.

  • doxorubicinDrug

    60mg/m\^2 via IV infusion, on Day 1 every three weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) as assessed by IRCTime frame: Up to approximately 4 years
  2. Overall Survival (OS)Time frame: Up to approximately 4 years

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Obstetrics and Gynecology Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • SUN Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • Xijing Hospital of Air Force Military Medical University

    Xi'an, Shaanxi, China · Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Sencond Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China · Not yet recruiting

  • Women's Hospital school of Medical Zhejiang University

    Hangzhou, Zhejiang, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.